AZOR
LOE Approachingamlodipine besylate and olmesartan medoxomil
NDAORALTABLET
Approved
Sep 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
6/8 — Strong
AZOR (amlodipine besylate and olmesartan medoxomil) is . Approved for hypertension, alone, other antihypertensive agents and 2 more indications. First approved in 2007.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AZOR is a fixed-dose combination of amlodipine besylate (a calcium channel blocker) and olmesartan medoxomil (an angiotensin II receptor blocker) administered orally as a tablet. It is indicated for hypertension management, either as monotherapy or in combination with other antihypertensive agents, and addresses the dual pathway inhibition of blood pressure regulation. The drug works by reducing vascular smooth muscle calcium influx and blocking angiotensin II-mediated vasoconstriction.
$0.003BPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with modest Part D utilization, suggesting a contracting brand team and reduced promotional resources.
Mechanism of Action
. Azor is a combination of two antihypertensive drugs: a dihydropyridine calcium antagonist (calcium ion antagonist or slow-channel blocker), amlodipine besylate, and an angiotensin II receptor blocker, olmesartan medoxomil. The amlodipine component of Azor inhibits the transmembrane influx of…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.